| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| COMPASS Pathways Plc | COMP360 psilocybin | Post-traumatic Stress Disorder (PTSD) | Phase 2/3 | IND Clearance | Oral | Psychiatric |
| COMPASS Pathways Plc | COMP360 psilocybin - (COMP005) | Treatment-resistant depression (TRD) | Phase 3 | Data Released | Oral | Psychiatric |
| COMPASS Pathways Plc | COMP360 psilocybin - (COMP006) | Treatment-resistant depression (TRD) | Phase 3 | Ongoing | Oral | Psychiatric |
| COMPASS Pathways Plc | COMP360 Psilocybin - (COMP004) | Treatment-Resistant Depression | Phase 2 | Data Released | Oral | Psychiatric |
| COMPASS Pathways Plc | COMP360 psilocybin | Anorexia nervosa | Phase 2 | Trial Planned | Oral | Psychiatric |
| Compass Therapeutics Inc. | CTX-009 - (COMPANION-003) | Colorectal cancer (CRC) | Phase 2 | Data Released | Intravenous | Oncology |
| Compass Therapeutics Inc. | CTX-471 (CD137 agonist) | Solid tumors | Phase 2 | Trial Planned | Intravenous | Oncology |
| Compass Therapeutics Inc. | CTX-471 with tovecimig (CTX-009) | Solid tumors | Phase 2 | Trial Planned | Intravenous | Oncology |